Symptoms and the Disease Spectrum
At a Glance
C9ORF72 expansions can cause a variable neurological spectrum that includes Huntington-like movement problems, frontotemporal dementia-like changes in behavior or thinking, and ALS-like weakness or swallowing difficulty. Many people do not develop all three symptom groups.
The C9ORF72 expansion is unique because it does not stay in one “lane.” While classic Huntington’s disease primarily affects movement and certain types of thinking, the C9ORF72 spectrum can involve symptoms from three distinct neurological areas: movement disorders, behavioral changes, and motor neuron disease [1][2].
Because this gene is also the leading cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), your symptoms may span a broad spectrum [2]. The presentation is highly variable; among the small subgroup presenting as an HD phenocopy, movement symptoms are prominent, while other carriers present with ALS, FTD, an overlap syndrome, or no symptoms [3][4]. It is not an inevitable progression across domains.
Domain 1: Huntington’s-Like Movement Symptoms
In patients with this HD-phenocopy expansion, a movement disorder that mimics Huntington’s disease is prominent [5]. These symptoms often involve the brain’s “autopilot” for movement, the basal ganglia.
- Chorea: Involuntary, dance-like, or jerky movements that can affect the limbs, face, or trunk [2].
- Parkinsonism: Symptoms that resemble Parkinson’s disease, such as bradykinesia (slowness of movement), muscle stiffness (rigidity), or tremors [1][6].
- Dystonia: Sustained or repetitive muscle contractions that result in twisting or abnormal fixed postures [7].
- Gait and Coordination: You may experience unsteady walking (ataxia) and difficulty with fine motor tasks, like buttoning a shirt [5][1].
Domain 2: Cognitive and Behavioral Symptoms (FTD-Like)
This expansion often affects the front and sides of the brain (the frontal and temporal lobes), which control personality, judgment, and language [8]. These features may appear long before or alongside movement issues [1][4].
- Personality Changes: You or your family may notice apathy (a deep loss of interest or motivation) or disinhibition (acting impulsively or inappropriately in social situations) [9][10].
- Psychosis and Delusions: Some reports suggest this variant may carry psychiatric features, including delusions (fixed false beliefs) or hallucinations (seeing or hearing things that aren’t there) [9][11].
- Executive Dysfunction: Difficulty planning, organizing, or multitasking. This can make simple daily routines feel overwhelming [10].
- Language Shifts: Difficulty finding the right words or understanding complex sentences, which is characteristic of the FTD side of the spectrum [12].
Domain 3: Motor Neuron Symptoms (ALS-Like)
The most critical way this condition differs from Huntington’s is the potential for motor neuron involvement [13]. This affects the nerves that send signals from your brain to your muscles.
- Muscle Weakness and Wasting: You may notice specific weakness in a hand or foot (like “foot drop,” where you trip over your toes) or visible muscle thinning (atrophy) [3][14].
- Fasciculations: Small, involuntary visible muscle twitching under the skin [3][14].
- Upper Motor Neuron Signs: This includes spasticity (unusual muscle tightness) and overly active reflexes [3][13].
- Bulbar Symptoms: Changes in the muscles of the mouth and throat can lead to dysarthria (slurred or “thick” speech) and dysphagia (difficulty swallowing) [13][15].
A Changing Landscape
It is important to remember that examination and testing are individualized. A person might begin their journey seeing a movement disorder specialist for chorea but may eventually need to see a neuromuscular specialist if weakness develops [3]. Because the C9ORF72 expansion is so variable, your medical team will monitor for all three domains [1]. While individuals with the expansion may show specific patterns of volume loss on brain imaging, such as in the thalamus or cerebellum, these MRI findings are supportive rather than diagnostic or prognostic of which phenotype will develop [16].
Common questions in this guide
What symptoms can a C9ORF72 expansion cause?
Does everyone with a C9ORF72 expansion develop Huntington-like symptoms?
How is the C9ORF72 spectrum different from classic Huntington disease?
Can C9ORF72 expansions cause hallucinations or delusions?
What motor neuron symptoms should I report?
Which specialists may help monitor C9ORF72 symptoms?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Symptoms to track
Which symptoms should I track and report to my care team?
Changes over time
Can symptoms shift between movement, behavior, and muscle domains over time?
Specialist care
Would I need to see a neuromuscular specialist if muscle weakness develops?
Get notified when new evidence is published on Huntington disease-like syndrome due to C9ORF72 expansions.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
C9orf72 and its Relevance in Parkinsonism and Movement Disorders: A Comprehensive Review of the Literature.
Bourinaris T, Houlden H
Movement disorders clinical practice 2018; (5(6)):575-585 doi:10.1002/mdc3.12677.
PMID: 30637277 - 2
Expanding the spectrum of C9ORF72-related neurodegenerative disorders in the Greek population.
Kartanou C, Kontogeorgiou Z, Rentzos M, et al.
Journal of the neurological sciences 2022; (442()):120450 doi:10.1016/j.jns.2022.120450.
PMID: 36252286 - 3
Atypical features including acquired oculomotor apraxia in C9orf72-associated familial primary lateral sclerosis.
Hostetler N, Zakutney S, Pringle CE, et al.
Journal of neuromuscular diseases 2026; (13(4)):808-816 doi:10.1177/22143602251380427.
PMID: 41004400 - 4
Motor neuron disease beginning with frontotemporal dementia: clinical features and progression.
Gromicho M, Kuzma-Kozakiewicz M, Szacka K, et al.
Amyotrophic lateral sclerosis & frontotemporal degeneration 2021; (22(7-8)):508-516 doi:10.1080/21678421.2021.1910309.
PMID: 34229542 - 5
C9orf72 Hexanucleotide Repeat in Huntington-Like Patients: Systematic Review and Meta-Analysis.
Alva-Diaz C, Alarcon-Ruiz CA, Pacheco-Barrios K, et al.
Frontiers in genetics 2020; (11()):551780 doi:10.3389/fgene.2020.551780.
PMID: 33240313 - 6
Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature.
Wilke C, Pomper JK, Biskup S, et al.
Journal of neurology 2016; (263(3)):558-74 doi:10.1007/s00415-016-8021-7.
PMID: 26810719 - 7
Hereditary chorea - what else to consider when the Huntington's disease genetics test is negative?
Malek N, Newman EJ
Acta neurologica Scandinavica 2017; (135(1)):25-33 doi:10.1111/ane.12609.
PMID: 27150574 - 8
Revisiting the neuropsychiatry of Huntington's disease.
Teixeira AL, de Souza LC, Rocha NP, et al.
Dementia & neuropsychologia 2016; (10(4)):261-266 doi:10.1590/s1980-5764-2016dn1004002.
PMID: 29213467 - 9
Schizophrenia Phenotype Preceding Behavioral Variant Frontotemporal Dementia Related to C9orf72 Repeat Expansion.
Sellami L, St-Onge F, Poulin S, Laforce R
Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology 2019; (32(2)):120-123 doi:10.1097/WNN.0000000000000189.
PMID: 31205123 - 10
Motor, cognitive and behavioural profiles of C9orf72 expansion-related amyotrophic lateral sclerosis.
Colombo E, Poletti B, Maranzano A, et al.
Journal of neurology 2023; (270(2)):898-908 doi:10.1007/s00415-022-11433-z.
PMID: 36308529 - 11
The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion.
Devenney EM, Landin-Romero R, Irish M, et al.
NeuroImage. Clinical 2017; (13()):439-445 doi:10.1016/j.nicl.2016.11.028.
PMID: 28116236 - 12
[C9orf72-associated frontotemporal dementia in the Russian population].
Shpilyukova YA, Fedotova EY, Berdnikovich ES, et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2020; (120(9)):98-106 doi:10.17116/jnevro202012009198.
PMID: 33081454 - 13
Phenotypical differences of C9ORF72 gene-positive and negative amyotrophic lateral sclerosis: a comparative case series.
White LM, Boardman J, Lilleker J, et al.
Journal of medical genetics 2023; (60(10)):1016-1020 doi:10.1136/jmg-2022-109016.
PMID: 37173134 - 14
Amyotrophic lateral sclerosis: a clinical review.
Masrori P, Van Damme P
European journal of neurology 2020; (27(10)):1918-1929 doi:10.1111/ene.14393.
PMID: 32526057 - 15
Phenotypical Characterization of C9ALS Patients from the Emilia Romagna Registry of ALS: A Retrospective Case-Control Study.
Ghezzi A, Gianferrari G, Baldassarri E, et al.
Genes 2025; (16(3)) doi:10.3390/genes16030309.
PMID: 40149460 - 16
Structural and functional brain signatures of C9orf72 in motor neuron disease.
Agosta F, Ferraro PM, Riva N, et al.
Neurobiology of aging 2017; (57()):206-219 doi:10.1016/j.neurobiolaging.2017.05.024.
PMID: 28666709
This page is for informational purposes only and does not constitute medical advice. A neurologist should interpret your symptoms and testing and guide individualized monitoring for C9ORF72-related disease.